Wells Fargo Downgrades Tokai Pharmaceuticals (TKAI) to Market Perform
Tweet
Share
E-mailGet Alerts TKAI Hot Sheet
Price: $0.61 --0%
Rating Summary:
3 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 18 | Down: 12 | New: 24
Rating Summary:
3 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 18 | Down: 12 | New: 24
Join SI Premium – FREE
Wells Fargo downgraded Tokai Pharmaceuticals (NASDAQ: TKAI) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Tokai Pharmaceuticals click here. For more ratings news on Tokai Pharmaceuticals click here.
Shares of Tokai Pharmaceuticals closed at $5.20 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fox Advisors Downgrades Seagate Technology (STX) to Equalweight
- Morgan Stanley Downgrades Cleveland-Cliffs (CLF) to Equalweight
- Citi Downgrades Sabra Healthcare REIT Inc. (SBRA) to Neutral
Create E-mail Alert Related Categories
DowngradesRelated Entities
Wells FargoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
